High AJCC staging (odds ratio 1.98; p < 0.001), the use of EGFR inhibitor (odds ratio 6.14; p < 0.001), high T‐staging (odds ratio 1.47; p < 0.001), and the presence of lymphovascular invasion (odds ratio 4.92; p < 0.001) increase predicted bone metastasis risk. Here, EGFR is linked to bone metastasis.